Lupus & antiphospholipid syndrome
Add-on sirolimus for the treatment of mild or moderate systemic lupus erythematosus via T lymphocyte subsets balance
Authors' conclusion
(2) Sirolimus add-on treatment ameliorated clinical involvement, serological abnormalities and disease activity without adverse reactions in patients with SLE.
Study context
- Population
- Patients with mild or moderate systemic lupus erythematosus (SLE)
- Participants
- 17 vs 20
- Exposure
- SLE patients before vs 6 months after add-on sirolimus; SLE patients vs healthy controls
- SLEn = 17
- Healthy controlsn = 20reference
- Outcome
- Clinical and immunological changes after add-on sirolimus
- Follow-up
- 6 months
Methodological detailssingle-group before–after, age- and sex-matched healthy controls
- Single-group before–after
- Age- and sex-matched healthy controls
Main finding
As reported in the abstract
6 months
- Urinary protein, pancytopenia, immunological indicators and SLEDAI-2K distinctively improved vs before sirolimus (p<0.05)
- Peripheral lymphocytes, T cells, T helper (Th) cells, Treg cells, Th2 cells and Treg/Th17 ratios higher after treatment than before (p<0.05)
- Plasma IL-5, IL-6 and IL-10 decreased, IL-4 increased vs pretreatment (p<0.05)
Observational data: associations, not effects.
Further findings
T cell subsets in SLE vs healthy controls
- Lymphocytes, T cells, Th, Treg, Th1, Th2 cells and Treg/Th17 ratios significantly lower, Th17 cells higher in SLE than healthy controls (p<0.05)
Original publication
Add-on sirolimus for the treatment of mild or moderate systemic lupus erythematosus via T lymphocyte subsets balance. Lupus Sci Med. Published 13 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →